Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Key Points

• Clene plans to file CNM-Au8 with the FDA in early Q4 2026 and expects a potential regulatory decision around mid-2027 if the application is accepted for review.
• Although CNM-Au8 missed the HEALEY trial’s primary ALSFRS endpoint, Clene says its data show survival, clinical-worsening and CAFS benefits, along with neurofilament changes linked to mortality risk.
• The company is pursuing potential accelerated approval with a confirmatory Phase III survival study and says recent financing provides enough cash to reach the FDA’s filing-acceptance decision.

Clene NASDAQ: CLNN said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS.

In a fireside chat at the Lytham Partners Fall 2026 Investor Conference, Chief Executive Officer Rob Etherington said the company expects the FDA to decide whether to accept the application for review. If accepted, he said Clene anticipates a review process that could lead to an FDA decision in the middle of 2027.

CNM-Au8 and Clene's Approach

Etherington described CNM-Au8 as an oral proprietary gold nanocrystal suspension and characterized Clene's approach as an intersection of physics, materials science and biology. He said the candidate is being studied in neurodegenerative diseases including ALS, multiple sclerosis and Parkinson's disease.

The company is not developing a conventional small-molecule drug or biologic, according to Etherington. He said CNM-Au8 is intended to support mitochondrial function and improve neuronal resilience. The drug is being used by patients in clinical studies as well as through four expanded-access protocols supporting compassionate use, he said.

Etherington emphasized the unmet need in ALS, a progressive and fatal neurological disease. He said patients commonly die within two to four years and that treatment options have historically been limited. He also noted that most ALS cases are heterogeneous and sporadic rather than associated with a specific genetic mutation.

Missed Endpoint, Survival and Biomarker Data

Clene's CEO acknowledged that the company missed the primary endpoint based on the ALS Functional Rating Scale, or ALSFRS, in the HEALEY study. ALSFRS measures patients' abilities across functions including movement, speech, eating and breathing.

However, Etherington said Clene believes other findings from its clinical program support an FDA submission. According to the CEO, CNM-Au8 showed a survival benefit, a statistically significant benefit on clinical worsening, and improvement on the Clinical Assessment of Function and Survival, or CAFS, measure in the company’s data.

He also pointed to changes in neurofilament light, a biomarker associated with neuronal injury. Etherington said Clene was the only regimen among eight assessed in the HEALEY program to show a nominally significant neurofilament light change in a double-blind, placebo-controlled study. He noted that the result was nominal because the study’s primary endpoint was not met.

The FDA has asked Clene to demonstrate that neurofilament reductions associated with CNM-Au8 are connected to survival, Etherington said. The company has compiled analyses that it says show a relationship between neurofilament trajectory and mortality risk, including results reproduced across independent studies.

“We’ve now taken all this data, and we have compiled an exhaustive new drug application,” Etherington said. He said the company has held five meetings with the FDA during the past two years and has sought to address the agency’s requests through clinical data and statistical models.

• Data supporting a survival benefit at a 30-milligram dose, according to the company.
• Analyses connecting neurofilament response with survival outcomes.
• Supplementary data from a rescue study.
• Evidence related to preservation of function and breathing capacity among predicted neurofilament responders.

Potential Regulatory and Commercial Milestones

Etherington said Clene is pursuing a potential accelerated-approval pathway that would be accompanied by a confirmatory Phase III study focused on survival in ALS patients. He said the company expects the FDA’s initial decision on whether to accept the application for review by the end of the year.

If CNM-Au8 were approved, Etherington said Clene believes the commercial opportunity could involve thousands of patients in the first year. He cited an estimate of roughly 4,000 patients for another therapy as a possible comparison point, while noting that Clene would need to work with insurers and government payers including Medicare and Medicaid to generate revenue.

The CEO also said Clene recently completed a financing and has sufficient cash to reach the FDA’s decision on whether it will accept the company’s new drug application for review.

Etherington thanked patients participating in Clene’s studies and expanded-access programs, stating that hundreds of people are currently receiving CNM-Au8 through compassionate use. He said the company has extensive long-term safety data and plans to update investors once it receives FDA feedback on the filing.

About Clene (NASDAQ:CLNN)

Clene Inc NASDAQ: CLNN is a clinical-stage biopharmaceutical company focused on developing nanotherapeutics for neurodegenerative diseases. The company's platform uses nanocrystals designed to influence cellular energy production and protect or restore the function of nerve cells.

Clene's leading investigational product is CNM-Au8, an orally administered suspension containing catalytically active gold nanocrystals. The therapy is being evaluated in clinical studies for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.